"Tumor Lysis Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.
| Descriptor ID |
D015275
|
| MeSH Number(s) |
C15.604.515.880 C20.683.515.950
|
| Concept/Terms |
Tumor Lysis Syndrome- Tumor Lysis Syndrome
- Syndrome, Tumor Lysis
- Syndromes, Tumor Lysis
- Tumor Lysis Syndromes
- Tumour Lysis Syndrome
- Syndrome, Tumour Lysis
- Syndromes, Tumour Lysis
- Tumour Lysis Syndromes
|
Below are MeSH descriptors whose meaning is more general than "Tumor Lysis Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Tumor Lysis Syndrome".
This graph shows the total number of publications written about "Tumor Lysis Syndrome" by people in this website by year, and whether "Tumor Lysis Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Lysis Syndrome" by people in Profiles.
-
Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
-
Baymon DE, Boyer EW. Chimeric antigen receptor T-cell toxicity. Curr Opin Pediatr. 2019 04; 31(2):251-255.
-
Kono H, Kimura Y, Latz E. Inflammasome activation in response to dead cells and their metabolites. Curr Opin Immunol. 2014 Oct; 30:91-8.
-
Blanchet GV, Allen HF, Mehrotra SP, Richardson MW. The tumor lysis syndrome in a child with multicentric Castleman disease. J Pediatr Hematol Oncol. 2010 Apr; 32(3):247-9.
-
Krishnan G, D'Silva K, Al-Janadi A. Cetuximab-related tumor lysis syndrome in metastatic colon carcinoma. J Clin Oncol. 2008 May 10; 26(14):2406-8.